Auris Medical Holding AG (EARS) and Histogenics Corporation (NASDAQ:HSGX) Comparing side by side

Both Auris Medical Holding AG (NASDAQ:EARS) and Histogenics Corporation (NASDAQ:HSGX) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auris Medical Holding AG N/A 0.00 N/A -1.94 0.00
Histogenics Corporation N/A 0.00 13.78M -0.43 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Auris Medical Holding AG and Histogenics Corporation.


Table 2 shows Auris Medical Holding AG and Histogenics Corporation’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Auris Medical Holding AG 0.00% 630.2% -100.9%
Histogenics Corporation 0.00% 66.4% -73.3%

Volatility and Risk

A beta of -1.07 shows that Auris Medical Holding AG is 207.00% more volatile than Standard and Poor’s 500. From a competition point of view, Histogenics Corporation has a 0.89 beta which is 11.00% less volatile compared to Standard and Poor’s 500.


The Current Ratio and Quick Ratio of Auris Medical Holding AG are 0.9 and 0.9 respectively. Its competitor Histogenics Corporation’s Current Ratio is 0.7 and its Quick Ratio is 0.7. Auris Medical Holding AG can pay off short and long-term obligations better than Histogenics Corporation.

Analyst Ratings

The table given features the ratings and recommendations for Auris Medical Holding AG and Histogenics Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Auris Medical Holding AG 0 0 0 0.00
Histogenics Corporation 0 2 0 2.00

Competitively the consensus target price of Histogenics Corporation is $3.5, which is potential 2,511.94% upside.

Institutional & Insider Ownership

Institutional investors held 11.3% of Auris Medical Holding AG shares and 17.8% of Histogenics Corporation shares. Competitively, insiders own roughly 6.2% of Histogenics Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Auris Medical Holding AG -8.82% -24.41% 97.3% -54.81% -86.45% -90.97%
Histogenics Corporation 8.67% -13.07% -25.83% -83.15% -75.9% -77.31%

For the past year Histogenics Corporation has weaker performance than Auris Medical Holding AG


On 4 of the 7 factors Histogenics Corporation beats Auris Medical Holding AG.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.